OIE RL for Marek S Disease Dr. Aly M. Fadly USA

OIE RL for « Marek’s Disease » – « Dr. Aly M. Fadly » – « USA »

OIE Reference Laboratory Reports
Activities in 2012

Instructions

This form should be used by an OIE Reference Laboratory to report activities that took place from January through December of the past year (2012), unless otherwise stated, and must be submitted by the end of January every year.

Only those activities that concern the disease (or topic) for which the laboratory is recognised by the OIE should be mentioned. The questionnaire structure follows the Terms of Reference (ToRs) for OIE Reference Laboratories, available at:

Each ToR (blue italicised text) has been placed as a heading covering the group of questions related to it.

Please note the red italicised text is given as guidance and should be deleted from your report and substitute with your data. Examples are based on past Annual Reports or have been invented.

The questionnaire represents a means of gathering information on activities carried out by OIE Reference Laboratories and making it available to OIE Member Countries and to the OIE Reference Laboratory network.

This annual report will remain available for consultation on the OIE web site:

(

ToR = OIE Term of Reference

ToR:To use, promote and disseminate diagnostic methods validated according to OIE Standards

Cell Culture

PCR

ToR:To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.

To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2.Did your laboratory produce or store imported standard reference reagents officially recognised by the OIE or other international bodies?

Yes No

3.Did your laboratory supply standard reference reagents to OIE Member Countries?

Yes No

1. Did your laboratory produce diagnostic reagents other than the OIE-approved standard reference reagents?

Yes No

1. Did your laboratory produce vaccines?

Yes No

1. Did your laboratory supply vaccines to OIE Member Countries?

Yes No

ToR:To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

1. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

Yes No

1. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

Yes No

Use of Polymerase Chain Reaction (PCR) in Diagnosis of Marek’s Disease and Reticuloendotheliosis in Formalin-Fixed, Paraffin- Embedded Tumorous Tissues. 2012. Proceedings American Veterinary Medical Association ; 149th AVMA Annual Convention, August 3-7. San Diego, CA. (To be submitted to peer-reviewed journal)

Lee, L. F., M. Heidari, H. M. Zhang, B. Lupiani, S. M. Reddy, and A. Fadly. Cell culture attenuation eliminates rMd5ΔMeq-induced bursal and thymic atrophy and renders the mutant virus as an effective and safe vaccine against Marek's disease. Vaccine. 30:5151-5158. 2012.

ToR:To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

1. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes No

1. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes No

ToR:To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

1. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes No

Study of distribution of Neoplastic Diseases of Retroviral Etiology of birds in Commercial Poultry Farms of Russian Federation

ToR:To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

1. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes No

1. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes No

1. What method of dissemination of information is most often used by your laboratory?

(Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals:...... 13

b) International conferences:...... 2

c) National conferences:...... 2

d) Other:...... Am. Assoc. of Avian Pathologists-web page

ToR: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

1. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes No

If the answer is yes, please provide the total number of trained persons for each of the following categories:

a) Technical visits:...... 6

b) Seminars:...... 0

c) Hands-on training courses:...... 0

d) Internships (>1 month):...... 2

ToR:To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

16.Does your laboratory have a Quality Management System certified according to an International Standard?

Yes No

17.Is your laboratory accredited by an international accreditation body?

Yes No

18.Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned? (See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2012, Chapter 1.1.3 or Manual of Diagnostic Tests for Aquatic Animals 2012, Chapter 1.1.1)

Yes No

ToR:To organise and participate in scientific meetings on behalf of the OIE

1. Did your laboratory organise scientific meetings on behalf of the OIE?

Yes No

1. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes No

ToR:To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

1. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes No

1. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes No

1. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes No

ToR:To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results.

1. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes No

ToR: To place expert consultants at the disposal of the OIE

1. Did your laboratory place expert consultants at the disposal of the OIE?

Yes No

______

List of Publication on Marek’s disease

1. Dunn, J.R., Silva, R.F., Lee, L.F., Witter, R.L. 2012. Competition between two virulent Marek's disease virus strains in vivo. Avian Pathology. 41(3):267-275.

1. Mays, J.K., Silva, R.F., Kim, T., Fadly, A.M. 2012. Insertion of reticuloendotheliosis virus long terminal repeat into a bacterial artificial chromosome clone of a very virulent Marek's disease virus alters its pathogenicity. Avian Pathology. 41(3):259-265

1. Lee, L.F., Heidari, M., Zhang, H., Lupiani, B., Reddy, S.M., Fadly, A.M. 2012.Cell culture attenuation eliminates rMd5deltaMeq-induced bursal and thymic atrophy and renders the mutant virus as an effective and safe vaccine against Marek's disease. Vaccine. 30 (34):5151-5158.

1. Yu, Y., Luo, J., Mitra, A., Chang, S., Tian, F., Zhang, H., Yuan, P., Zhou, H., Song, J. 2012. Temporal transcriptome changes induced by MDV in Marek's disease-resistant and -susceptible inbred chickens. Biomed Central (BMC) Genomics. 12:501. Available:

1. Cheng, H.H., Maceachern, S., Subramaniam, S., Muir, W.M. 2012. Chicks and single-nucleotide polymorphisms: an entree into identifying genes conferring disease resistance in chicken. Animal Production Science. 52(3). Available:

1. Chang, S., Dunn, J.R., Heidari, M., Lee, L.F., Ernst, C.W., Song, J., Zhang, H. 2012. Vaccine by chicken line interaction alters the protective efficacy against challenge with a very virulent plus strain of Marek's disease virus in white leghorn chickens. World Journal of Vaccines. 2(1):1-11.

1. Luo, J., Yu, Y., Chang, S., Tian, F., Zhang, H., Song, J. 2012. DNA methylation fluctuation induced by virus infection differs between MD resistant and -susceptible chickens. Frontiers in Genetics. 3(20):1-15.

1. Tian, F., Luo, J., Zhang, H., Chang, S., Song, J. 2012. MiRNA expression signatures induced by Marek disease virus infection in chickens. Genomics. 99 (3):152-159.

1. Kumar, S., Kunec, D., Buza, J.J., Chiang, H.I., Zhou, H., Subramaniam, S., Pendarvis, K., Cheng, H.H., Burgess, S.C. 2012. Nuclear Factor kappa B is central to Marek’s Disease herpesvirus induced neoplastic transformation of CD30 expressing lymphocytes in-vivo. BMC Systems Biology. 6(123). Available:

1. Yuan, P., Yu, Y., Luo, J., Tian, F., Zhang, H., Chang, S., Ramachandran, R., Song, J. 2012. Comparative study of lipoprotein metabolism in Marek's disease susceptible and resistant chickens. Poultry Science. 91:2598-2605. Available:

1. Fei, T., Luo, J., Zhang, H., Chang, S., Song, J. 2012. Marek's disease virus challenge induced immune-related gene expression and chicken repeat 1 (CR1) methylation alterations in chickens. American Journal of Molecular Biology (AJMB). 2(2012):232-241. Available:

1. Dunn, J.R., Silva, R.F. 2012. Ability of MEQ-deleted MDV vaccine candidates to adversely affect lymphoid organs and chicken weight gain. Avian Diseases. 56:494-500.

1. Xu, M., Fitzgerald, S.D., Zhang, H., Karcher, D.M., Heidari, M. 2012. Very virulent plus strains of MDV induce acute form of transient paralysis in both susceptible and resistant chicken lines. Viral Immunology. 25(4):306-323.

Annual reports of OIE Reference Laboratories, 20121